Compare · INMD vs NUWE
INMD vs NUWE
Side-by-side comparison of InMode Ltd. (INMD) and Nuwellis Inc. (NUWE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both INMD and NUWE operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- INMD is the larger of the two at $912.4M, about 293.4x NUWE ($3.1M).
- Over the past year, INMD is up 1.0% and NUWE is down 97.2% - INMD leads by 98.3 points.
- NUWE has been more active in the news (7 items in the past 4 weeks vs 1 for INMD).
- INMD has more recent analyst coverage (20 ratings vs 1 for NUWE).
- Company
- InMode Ltd.
- Nuwellis Inc.
- Price
- $14.40+0.14%
- $1.16-0.43%
- Market cap
- $912.4M
- $3.1M
- 1M return
- +4.80%
- +4.50%
- 1Y return
- +1.02%
- -97.24%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- News (4w)
- 1
- 7
- Recent ratings
- 20
- 1
InMode Ltd.
InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies. The company offers minimally-invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. InMode Ltd. offers its products directly in United States, Canada, United Kingdom, Spain, India, Australia, and France, as well as through distributors in 47 countries. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was founded in 2008 and is headquartered in Yokneam, Israel.
Nuwellis Inc.
Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood set, and catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria, Brazil, Brunei, Germany, Greece, Hong Kong, India, Israel, Italy, Palestine, Singapore, Spain, Switzerland, Thailand, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
Latest INMD
- InMode to Report First Quarter 2026 Financial Results and Hold Conference Call on May 6, 2026, Expects Q1 Revenue Between $81.5M-$81.7M, Reiterates FY 2026 Revenue Guidance Between $365M-$375M
- InMode to Present at the 25th Annual Needham Virtual Healthcare Conference
- SEC Form 3 filed by InMode Ltd.
- SEC Form 3 filed by InMode Ltd.
- SEC Form 3 filed by new insider Mizrahy Moshe
- SEC Form 3 filed by new insider Kreindel Michael
- SEC Form 3 filed by InMode Ltd.
- SEC Form 3 filed by InMode Ltd.
- SEC Form 3 filed by InMode Ltd.
- SEC Form 6-K filed by InMode Ltd.
Latest NUWE
- Nuwellis Inc. filed SEC Form 8-K: Other Events
- Nuwellis to Participate in the AATS 106th Annual Meeting and ERAS Cardiac Spring Retreat
- Nuwellis Announces Aquadex Software Update
- Nuwellis Welcomes Back Three Former Team Members to Accelerate Commercial and Clinical Momentum
- Nuwellis Engages CORE IR for Public Relations, Shareholder Communications, and Social Media Management Services
- Nuwellis Strengthens Commercial Infrastructure with New South Texas Territory
- SEC Form DEFA14A filed by Nuwellis Inc.
- SEC Form DEF 14A filed by Nuwellis Inc.
- Amendment: Nuwellis Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Nuwellis Pediatric Category Achieves Approximately 50% of Total U.S. Revenue in 2025, Marking Growth Milestone